Viridian: Priority Review for Veligrotug and Catalyst-Rich 2026 Outlook Drive Price Target Raise and Buy Rating

Needham analyst Serge Belanger maintained a Buy rating on Viridian Therapeutics today and set a price target of $42.00.

Serge Belanger has given his Buy rating due to a combination of factors tied to Viridian’s accelerated regulatory and commercial outlook. The FDA’s decision to grant veligrotug a Priority Review, with a PDUFA date set for June 30, 2026, pulls forward the expected approval and launch by roughly half a year versus prior expectations, improving the near- to mid‑term revenue visibility. This earlier potential launch in the first half of 2026 meaningfully enhances the company’s valuation profile and supports a more constructive risk‑reward setup for the stock.

In addition, Belanger has refreshed his financial model to account for both the revised veligrotug timeline and anticipated contributions from VRDN‑003, with Phase 3 REVEAL data expected in the first and second quarters of 2026. These upcoming pivotal readouts, combined with the possibility of FDA approval within the same time frame, create a concentrated period of catalysts that could materially transform Viridian’s business. Reflecting these improved prospects, he raises his price target to $42 from $34 and reiterates a Buy rating to capture the upside he sees from this catalyst‑rich 2026 outlook.

In another report released today, Wedbush also maintained a Buy rating on the stock with a $47.00 price target.